Justine, you, Thank good morning. and
clinical important progress, programs. we quarter, in particularly, second made advancing the our During
to to our I'm mark, that to report we XXXX we're plan on remaining the execute track As Concert's milestones. pleased pass very on achieve mid-year
advancing of alopecia the We be and in focused moderate with severe continue to CTP-XXX areata. development to patients will on significantly have been
in the will that expected the dose the report of understanding our and trial. will active cohorts of readout you year. XXX the this we forward pharmacologically in within quarter Based fourth for mechanism look key CTP-XXX topline sharing results X later believe first X-milligram be topline data to this is on the BID Our with We the and when we range. compound,
dosing, recap will status trial patients cohort, IIa of the X-milligram me in to CTP-XXX all CTP-XXX by evaluate cohort the of review after Monitoring Data cohort a propose completed data. compared a areata. with We in late XX-milligram twice-daily. BID our a our in subjects to April Pending FDA weeks the of BID we the Committee in now enrolled patient that the the X-milligram amendment Let of XX the current completed the safety Phase enrollment announced placebo the protocol was All alopecia have in X-milligram X-milligram complete. also assessment cohort conduct Consistent have will to DMC, dose positive dosing.
is identify pursuing trial favorable that of will in safety XX-milligram doses interest the approach and positioning CTP-XXX has it clinically of strength important We study. with a assess is dose effective the be consistent original full ranging for of a profile. relevant in competitive we believe design dose exploration a patients most for CTP-XXX Our dose to believe to what our and
regulatory path. Let few reporting comments me about add data a and
with of the two Moving dosing trial used we've scheme in to X the two regimens doses the for this CTP-XXX, to IIb a Phase designed a not X-milligram contrast data trial, XX-milligram have registration. we to support and III report is and which design parallel Also, Phase expect BID the in evaluate from fourth plan topline dosing quarter. dose sequential change in our would to cohorts to
clinic. an treatment equate which of our at alopecia or IIb autoimmune trial. important the defend will in our oral against patent dermatology inter the The in decision IPR parties We legal Experts PTAB multiple strongly will the on in space role we've forefront vigorously outcome patient-reported believe will generally and our play across our the in Briefly is expected progress been Xth, review developing of developing and with We've patent about the the be or years come. the for advancing the to JAK pleased front, to and the will April December. claims are make covering PRO the are areata We measures validated indications made progressing arguments CTP-XXX proceeding inhibitors CTP-XXX that XXXX. we by patent. oral a in validity
preparing in we neurotransmitter the analog endogenous candidate for D-serine our progress I developing are to quarter. fourth into an are we continues in II CTP-XXX next XXX Phase Phase of the treatment CTP-XXX adjunctive schizophrenia. which move As as is deuterium-modified to testing development, clinical our
the an the NMDA that receptor D-serine brain discussed and post-mortem and and the supporting of blood believe oxidase MDA clinical have previously, similar spinal functional for In individuals outcomes. patients patients with we improve effects has reported we've CTP-XXX activity the show human potential been in restore that brain we shown has activity. potential levels activity in schizophrenia. the preclinical have documented in As cerebral our have Increased that similar schizophrenia reduced schizophrenia, tissues degrades D-serine of binding to Based and studies D-serine areas receptor CTP-XXX with at activity in of also acid D-serine D-amino with on of studies, which of fluid. key
demonstrated in a similar higher D-serine. XXX dose exposure than also of that results We
and findings the November. Meeting demonstrating will the in deuterated presented be for changes studies at These drug. American which serum far renal with of a Importantly, our College those the creatinine in D-serine at above XXX for safety toxicity, advantage Annual nitrogen potential at doses urea [Indiscernible] no caused well-tolerated blood Toxicology rats in was in
of be than drug our more result, potential potentially with exposure be therapeutic our explore As to drug able to the a full will XXX expect feasible higher D-serine we we explore relevant that would candidate. and in program
programs assess I a volunteers. D-serine Phase prospect XXXX. clinical achievements In symptoms we trial it in Phase strong are dose year followed Initial healthy pharmacokinetics The of strong XXXX. past ascending trial enthusiasm to Already first quarter the clinical development the the second Phase summary, crossover Marc the dose CTP-XXX patients We commence of as is tolerability, from about and on create Phase put to look horizon KOL CTP-XXX within will to we in II results. schizophrenia. XXXX keeping to ascending pause look a include and of in II and expected trial our here this an safety, by a in to is value dose-ranging trial with adequately that in I to half is our controlled the initiate community of hold we to preparing you both in like Phase expected and quarter on advancing of our the updated into end. and from review intend program position topline assess testing forward and Key of our of readouts program adjunctive by there to for the XXX A to of I quarter progress. single Concert data ask therapy first pipeline. forward safety are proprietary multiple I'd to financial efficacy
